The guidance report does not say COVID-19 vaccines are causing myocarditis and pericarditis. The report has been misinterpreted.
On December 7, 2021, the UKHSA delivered a clinical guidance report "to support the detection and management of clinical cases of myocarditis and pericarditis associated with COVID-19 vaccination." Although the report stated that the condition was usually observed in people inoculated with Pfizer-BioNTech and Moderna mRNA vaccines, the cases of myocarditis of the COVID-19 vaccine were rare and generally mild. Most patients who show symptoms of myocarditis recover quickly. Moreover, people are more likely to get myocarditis if they have a COVID-19 infection.
Myocarditis and pericarditis are both rare condition that causes heart muscle inflammation. Research published in the American Heart Association's journal reviewed the medical records of 139 young patients. It stated that most young people under 21 years who developed suspected COVID-19 vaccine-related myocarditis had mild symptoms that improved quickly. Also, no patients died or required mechanical support for blood circulation due to the condition.
COVID-19 vaccines were developed using scientific approaches that have been around for years, and COVID-19 vaccines approved for emergency use are safe and effective at preventing the COVID-19 infection.
According to the reports of myocarditis and pericarditis following the COVID-19 vaccination received by the MHRA, the overall rate of myocarditis and pericarditis was low, and most cases are mild or stable. As of November 17, 2021, the condition was reported in 10 per million doses with the Pfizer-BioNTech vaccine and 7 per million doses for pericarditis.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19, including symptoms, prevention, and available treatment, please refer to the World Health Organization or your national healthcare authority.